Pharma & Biotech

Sysmex Corporation has announced the acquisition of JEOL's clinical chemistry testing business, which includes the BioMajesty product line. The company's...

Bayer's pharmaceutical division has encountered a significant clinical development hurdle as its promising heart failure drug candidate, Vericiguat, failed to...

In the intensifying battle for dominance in the multi-billion dollar weight-loss drug market, Novo Nordisk has delivered a powerful counterpunch....

Iovance Biotherapeutics finds itself at a critical juncture as it prepares for significant investor conferences in early September. These events...

Pharmaceutical giant Eli Lilly, already reaping billions from its revolutionary weight-loss and diabetes treatments, may be on the verge of...

Cardiff Oncology enters a crucial period with three major investor conferences scheduled for early September, providing the biotechnology firm with...

Sarepta Therapeutics finds itself at a pivotal crossroads as it transitions from the S&P MidCap 400 to the S&P SmallCap...

Biotech firm Replimune confronts a pivotal moment for its future as it engages in a decisive Type-A meeting with U.S....

Axsome Therapeutics finds itself navigating a complex landscape as generic manufacturer Apotex Inc. launches a legal challenge against the market...

A significant regulatory milestone in Europe has positioned Abbott Laboratories for accelerated growth within its structural heart business. The medical...